COVID-19 vaccine-related interstitial lung disease: a case study

Park, Ji Young; Kim, Joohee; Lee, In Jae; Kim, Hwan Il; Park, Sunghoon; Hwang, Yong Il; Jang, Seung Hun; Jung, Ki‐Suck

doi:10.1136/thoraxjnl-2021-217609

Cited by 37 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Park et al . has reported a case of SARS-CoV-2 vaccine-related ILD [ 10 ], and the WHO global pharmacovigilance database (VigiAccess) showed 464 cases of suspected ILD, 87 cases of suspected organising pneumonia, eight cases of acute lung injury and two cases of acute interstitial pneumonitis and idiopathic interstitial pneumonia from the BNT162b2 vaccine. However, no AE-f-ILD cases were seen [ 11 ], nor was AE-f-ILD reported in a clinical trial [ 2 ].…”

mentioning

confidence: 99%

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread worldwide and coronavirus disease 2019 remains a top health concern. Several SARS-CoV-2 vaccines have been produced and are playing great roles in the prevention of infection and worsening to a severe state, and in improving mortality [1]. However, some concerns about adverse effects related to SARS-CoV-2 vaccination have been raised. Recently, various adverse effects have been reported, but there is little data on adverse effects on the lungs [2].

show abstract

mentioning

confidence: 99%

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 2 Thus far, only one case of interstitial pneumonitis after COVID-19 vaccination has been reported from South Korea: the patient was an 86-year-old man with multiple comorbidities. 9 Because clinical trials for vaccines have largely enrolled younger, relatively healthy adults, it is important to evaluate the safety of these vaccines in all age populations, especially older individuals with severe underlying disease. Although risk factors remain unknown, preexisting interstitial lung disease is associated with an increased likelihood of drug-induced pneumonitis.…”

mentioning

confidence: 99%

Interstitial pneumonitis after COVID-19 vaccination: A report of three cases

Shimizu

Watanabe

Yoneda

et al. 2022

Allergology International

View full text Add to dashboard Cite

“…The first and second doses cause the same side effects with minimal increased or decreased percentages [53]. Rare side effects related to mRNA based SARS-CoV2 vaccination were reported as well, including interstitial lung disease [64], rosaceiform eruption [65], peripheral facial nerve palsy [66], anaphylactic reactions (~1/1 million) [67], Guillain-Barre Syndrome [68], myocarditis [69], thrombocytopenia [70] and purpuric rash (Moderna) [71], systemic inflammatory response syndrome (SIRS) (Moderna) [72], myocardial infarction [73][74][75], anaphylaxis [76], hearing loss and tinnitus [77]. These rare adverse effects are mostly confined to cases, and it is not possible claim that vaccine itself caused the problem, but it might worsen the present problem, particularly for systemic inflammatory response syndrome [72].…”

Section: Side-effects Of Mrna Sars-cov2 Vaccinesmentioning

confidence: 83%

mRNA SARS-CoV2 Specific and Childhood Vaccines against Covid-19 Pandemic

YAZGAN

2021

Türk Doğa Ve Fen Dergisi

View full text Add to dashboard Cite

The coronavirus disease 2019 (Covid-19) pandemic has been challenging the entire world since early 2020. Due to the fact that there is no universally available treatment method along with the disease's fast transmission from human to human, specific vaccine development efforts have got a great attention. Particularly mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) specific vaccines are administrated to individuals worldwide to combat against Covid-19 infection. Even though two dose mRNA vaccination provides immunity against ancestral and aggressive variants of SARS-CoV2 infections, rare detrimental short-time side effects and no-data availability on long-term possible side-effects along with unpredictable vaccination regime bring hesitancy against the vaccines. Besides, the vaccination regime is still under debate among the scientist as that whether pre-infected individuals require further vaccination and what should be the ideal vaccination dose. In addition to mRNA SARS-CoV2 specific vaccines, recent retrospective, theoretical, clinical, and biochemical studies revealed that trained innate immunity and heterologous T-cells and memory B-cells can be strong alternative to combat against SARS-CoV2 pandemic. In this context, conventional childhood vaccines (e.g., BCG and MMR) are proposed as valuable alternative vaccines against the pandemic with known clinical outcomes and effectivity. Covid-19'a karşı mRNA SARS-CoV2 spesifik ve Çocukluk Dönemi AşılarıAnahtar Kelimeler SARS-CoV2, mRNA aşıları, Klasik aşılar, Bağışıklık Öz: 2019 yılı koronavirus hastalığı (Covid-19) pandemisi 2020 yılından beri dünya çapında bir sorun haline gelmiştir. Evrensel olarak kabul edilmiş bir tedavisinin olmayışı ve insandan-insana geçişinin hızlı olması nedeniyle spesifik aşı geliştirme çalışmaları önem kazanmıştır. mRNA-temelli ağır akut solunum yolu yetersizliği sendromu korovirus 2 (SARS-CoV2) aşıları dünya çapında Covid-19'un kontrol altına alınmasına yönelik olarak en yaygın olarak kullanılan aşılardır. Herne kadar iki doz mRNA aşılarının hem atasal hemde mutasyona uğramış agresif SARS-CoV2 viral enfeksiyonlarına karşı yüksek bağışıklık sağlıyor olmalarına karşın, nadir olarak görülen kısa dönem yan etkileri ve uzun dönemli olası yan etkileri hakkında bilgilerin mevcut olmaması nedeniyle aşılara karşı bir tereddüt mevcuttur. Buna ek olarak, aşılama rejimin nasıl olması gerektiği bilimadaları arasında hala tartışma konusudur, örneğin enfeksiyon geçirmiş olan bireyler tekrar aşı olmalı mı ve kaç doz aşı olunması gerekir. mRNA temelli SARS-CoV2 aşılarına alternatif olarak, yeni yapılan retrospektif, teorik, klinik ve biyokimyasal çalışmalar, eğitilmiş doğal bağışıklığın ve heterelog T-hücrelerinin ve hafıza B hücrelerinin SARS-CoV2 pandemisine karşı savaşta önemli bir alternatif olabileceği önerilmiştir. Bu kapsamda, klasik çocukluk dönemi aşılarının (örneğin BCG ve MMR) pandemiye karşı bilinen klinik souçları ve etkinliği nedeniyle önemli alternatif aşılar oldukları görülmektedir.

show abstract

COVID-19 vaccine-related interstitial lung disease: a case study

Cited by 37 publications

References 13 publications

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

Interstitial pneumonitis after COVID-19 vaccination: A report of three cases

mRNA SARS-CoV2 Specific and Childhood Vaccines against Covid-19 Pandemic

Contact Info

Product

Resources

About